Cullen Breda M, Serena Thomas E, Gibson Molly C, Snyder Robert J, Hanft Jason R, Yaakov Raphael A
Breda M. Cullen, PhD, is Scientific Program Manager, Systagenix, Gargrave, United Kingdom. Thomas E. Serena, MD, FACS, FACHM, MAPWCA, is Founder, Medical Director, and CEO, SerenaGroup, Cambridge, Massachusetts. Molly C. Gibson, BSc, is Assistant Scientist, Systagenix, Gargrave, United Kingdom. Robert J. Snyder, DPM, MSc, is Professor, Barry University School of Podiatric Medicine, Miami Shores, Florida. Jason R. Hanft, DPM, FACFAS, is Director of Education, South Miami Hospital, South Miami, Florida. Raphael A. Yaakov, MS, is Clinical Project Lead, SerenaGroup, Cambridge, Massachusetts.
Adv Skin Wound Care. 2017 Oct;30(10):464-468. doi: 10.1097/01.ASW.0000524452.80170.d8.
To assess healing outcomes in venous leg ulcers (VLUs) treated with a combination of collagen, oxidized regenerated cellulose, and silver in conjunction with standard of care (SOC; intervention group) compared with SOC alone (control group). Standard of care included ADAPTIC nonadhering dressing (Acelity, San Antonio, Texas) and compression.
Randomized controlled trial that followed patients in 3 US facilities for 12 weeks or until complete healing.
Forty-nine patients with VLUs were randomized to either the intervention group (n = 22) or the control group (n = 27).
Wound healing over 12 weeks.
Intent-to-treat analysis showed a mean percentage wound area reduction at 12 weeks of 85.6% (SD, 28.6%) for the intervention group and 72.5% (SD, 77.8%) for the control group. There was a higher healing rate in the intervention group compared with patients who received SOC only at both week 4 (23% vs 11%) and week 12 (64% vs 59%). There were no adverse events related to the study therapy.
Although the results were not significant, there was a trend toward faster healing in the intervention group. The results of this study indicate that collagen/oxidized regenerated cellulose/silver is a suitable and safe adjunctive intervention for use with SOC to manage VLUs.
评估在标准治疗(SOC)基础上联用胶原蛋白、氧化再生纤维素和银治疗下肢静脉溃疡(VLU)的愈合效果(干预组),并与单纯SOC治疗(对照组)进行比较。标准治疗包括使用ADAPTIC非粘连敷料(Acelity公司,得克萨斯州圣安东尼奥)和加压治疗。
一项随机对照试验,在美国3家机构对患者进行为期12周的随访,直至完全愈合。
49例VLU患者被随机分为干预组(n = 22)或对照组(n = 27)。
12周内伤口愈合情况。
意向性分析显示,干预组在12周时伤口面积平均减少百分比为85.6%(标准差,28.6%),对照组为72.5%(标准差,77.8%)。与仅接受SOC治疗的患者相比,干预组在第4周(23%对11%)和第12周(64%对59%)的愈合率更高。未出现与研究治疗相关的不良事件。
尽管结果不显著,但干预组有愈合更快的趋势。本研究结果表明,胶原蛋白/氧化再生纤维素/银是一种适合且安全的辅助干预措施,可与SOC联合用于治疗VLU。